Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x
Impact News +++ Bunge Diverts Argentina Soybean Meal Ship Bound for China (Bloomberg) +++ BUNGE Aktie +3,10%

ACTINIUM Aktie

 >ACTINIUM Aktienkurs 
1.437 EUR    +0.8%    (Tradegate)
Ask: 1.429 EUR / 2100 Stück
Bid: 1.393 EUR / 2200 Stück
Tagesumsatz: 54 Stück
Realtime Kurs von 8 bis 22 Uhr!
ACTINIUM Aktie über LYNX handeln
>ACTINIUM Performance
1 Woche: +9,8%
1 Monat: -2,1%
3 Monate: -4,3%
6 Monate: +28,4%
1 Jahr: -23,1%
laufendes Jahr: +27,8%
>ACTINIUM Aktie
Name:  ACTINIUM PHARMAC. DL-,001
Land:  USA
Sektor:  Gesundheit
ISIN/ Wkn:  US00507W2061 / A2QA48
Symbol/ Ticker:  7AY1 (Frankfurt)
Kürzel:  FRA:7AY1, ETR:7AY1, 7AY1:GR
Index:  -
Webseite:  https://www.actiniumpharm..
Profil:  Actinium Pharmaceuticals Inc. is a clinical-stage ..
>Volltext..
Marktkapitalisierung:  45.69 Mio. EUR
Unternehmenswert:  -4.03 Mio. EUR
Umsatz:  -
EBITDA:  -37.2 Mio. EUR
Nettogewinn:  -35.15 Mio. EUR
Gewinn je Aktie:  -1.13 EUR
Schulden:  1.1 Mio. EUR
Liquide Mittel:  51.33 Mio. EUR
Operativer Cashflow:  -26.29 Mio. EUR
Bargeldquote:  7.21
Umsatzwachstum:  -100%
Gewinnwachstum:  12.46%
Dividende je Aktie:  -
Dividendenrendite:  -
Dividendenschätzung:  -
Insiderhandel:  -
Suchwörter:  ACTINIUM
Letzte Datenerhebung:  20.08.25
>ACTINIUM Kennzahlen
Aktien/ Unternehmen:
Aktien: 31.2 Mio. St.
Frei handelbar: 97.46%
Leerverk. Aktien: -
Rückkaufquote: -8.63%
Mitarbeiter: 37
Umsatz/Mitarb.: -
Analysten:
Analystenrating: Strong buy
Kursziel: 243.33%
Bewertung:
KGV: -
KGV lG: -
KUV: -
KBV: 2.76
PEG-Ratio: -
EV/EBITDA: -
Rentabilität:
Bruttomarge: -
Gewinnmarge: -
Operative Marge: -
Managementeffizenz:
Gesamtkaprendite: -53.68%
Eigenkaprendite: -130.59%
>ACTINIUM Peer Group

Es sind 601 Aktien bekannt.
 
31.07.25 - 14:33
 Actinium Presents Data Supporting Paradigm Changing Potential of ATNM-400 in Prostate Cancer Demonstrating Its Superior Efficacy and Improved Survival in Treatment Resistant Tumor Models versus Pluvicto and ARPI Therapy, and Also Enhanced Efficacy in (PR Newswire)
 
- ATNM-400 demonstrates robust efficacy in prostate cancer tumor models with acquired resistance to Pluvicto® and enzalutamide, follow-up continues - ATNM-400 significantly improved survival compared to the approved prostate cancer treatment Pluvicto®, the first blockbuster radiotherapy -......
26.06.25 - 14:09
 Cellectar Biosciences and U.S.-based Nusano Enter Into Multi-Isotope Supply Agreement (GlobeNewswire EN)
 
Partnership Provides Long-Term Supply of Iodine-125 and Actinium-225...
23.06.25 - 17:33
 Actinium Highlights Expanded Data Set for ATNM-400 in Prostate Cancer Demonstrating Superior Efficacy to Enzalutamide and Ability to Overcome Resistance to ARPI Therapy and PSMA-Ac-225/Lu-177 Labelled Radiotherapy at the Society of Nuclear Medicine & (PR Newswire)
 
- ATNM-400 shows; superior prostate cancer cell killing compared to androgen receptor inhibitor Xtandi® (enzalutamide), the ability to overcome Xtandi resistance, and activity in combination - ATNM-400 is more efficacious than both Pluvicto® (177-Lu-PSMA-617) and Ac-225-PSMA-617 targeted......
20.06.25 - 14:03
 Ratio Therapeutics and TerraPower Isotopes Sign Supply Agreement for Actinium-225 For Targeted Radiotherapeutics (PR Newswire)
 
BOSTON and BELLEVUE, Wash., June 20, 2025 /PRNewswire/ -- Ratio Therapeutics Inc. (Ratio), a pharmaceutical company employing innovative technologies to develop best-in-class radiopharmaceuticals for cancer treatment and monitoring, and TerraPower Isotopes, a subsidiary of TerraPower, a......
20.06.25 - 13:36
 IONETIX Corporation and AlfaRim Medical B.V. announce a strategic partnership to fast-track commercial production of Actinium-225 (PR Newswire)
 
LANSING, Mich. and DELFT, Netherlands, June 20, 2025 /PRNewswire/ -- IONETIX, a leading cyclotron technology innovator and full-service isotope manufacturer, and AlfaRim, a Dutch deeptech company pioneering industrial-scale production of cGMP-grade Actinium-225, today announced a......
17.06.25 - 14:03
 Ratio Therapeutics and Nusano Enter Long-Term, Multi-Isotope Supply Agreement to Boost Production of Cancer Radiopharmaceuticals (PR Newswire)
 
Agreement provides Ratio access to Nusano-produced radioisotopes for oncology diagnostics and therapeutics Accelerates Ratio's clinical pipeline with copper-64 for PET imaging and lutetium-177 and actinium-225 for targeted therapy Bolsters both companies' manufacturing and supply chain......
10.06.25 - 17:39
 Kuehn Law Encourages Investors of Actinium Pharmaceuticals, Inc. to Contact Law Firm (PR Newswire)
 
NEW YORK, June 10, 2025 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Actinium Pharmaceuticals, Inc. (NYSE: ATNM) breached their fiduciary duties to shareholders. According to a federal securities lawsuit,......
26.05.25 - 14:36
 ATNM Deadline: ATNM Investors with Losses in Excess of $100K Have Opportunity to Lead Actinium Pharmaceuticals, Inc. Securities Fraud Lawsuit (PR Newswire)
 
NEW YORK, May 26, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) between October 31, 2022 and August 2, 2024, both dates inclusive (the "Class Period"), of the important......
23.05.25 - 11:45
 Class Action Filed Against Actinium Pharmaceuticals, Inc. (ATNM) - May 27, 2025 Deadline to Join - Contact Levi & Korsinsky (PR Newswire)
 
NEW YORK, May 23, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Actinium Pharmaceuticals, Inc. ("Actinium" or the "Company") (NYSE: ATNM) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Actinium investors who were......
22.05.25 - 16:30
 ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Actinium (PR Newswire)
 
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Actinium To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $75,000 in Actinium between October 31, 2022 and August 2, 2024......
22.05.25 - 11:45
 The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 27, 2025 in Actinium Lawsuit - ATNM (PR Newswire)
 
NEW YORK, May 22, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Actinium Pharmaceuticals, Inc. (NYSE: ATNM). Shareholders who purchased shares of ATNM during the class period listed are encouraged to contact the firm regarding possible lead......
22.05.25 - 00:01
 ATNM Deadline: ATNM Investors with Losses in Excess of $100K Have Opportunity to Lead Actinium Pharmaceuticals, Inc. Securities Fraud Lawsuit (PR Newswire)
 
NEW YORK, May 21, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) between October 31, 2022 and August 2, 2024, both dates inclusive (the "Class Period"), of the important......
20.05.25 - 11:48
 Investors in Actinium Pharmaceuticals, Inc. Should Contact Levi & Korsinsky Before May 27, 2025 to Discuss Your Rights - ATNM (PR Newswire)
 
NEW YORK, May 20, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Actinium Pharmaceuticals, Inc. ("Actinium" or the "Company") (NYSE: ATNM) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Actinium investors who were......
19.05.25 - 19:09
 Contact The Gross Law Firm by May 27, 2025 Deadline to Join Class Action Against Actinium Pharmaceuticals, Inc. (ATNM) (PR Newswire)
 
NEW YORK, May 19, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Actinium Pharmaceuticals, Inc. (NYSE: ATNM). Shareholders who purchased shares of ATNM during the class period listed are encouraged to contact the firm regarding possible lead......
16.05.25 - 23:01
 ATNM Investors Have Opportunity to Lead Actinium Pharmaceuticals, Inc. Securities Fraud Lawsuit (PR Newswire)
 
NEW YORK, May 16, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) between October 31, 2022 and August 2, 2024, both dates inclusive (the "Class Period"), of the important......
16.05.25 - 16:24
 Faruqi & Faruqi Reminds Actinium Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 1, 2025 - CIVI (PR Newswire)
 
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Civitas To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $100,000 in Civitas between February 27, 2024 and February 24,......
16.05.25 - 15:42
 Faruqi & Faruqi Reminds Actinium Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 11, 2025 - ELV (PR Newswire)
 
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Elevance To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $100,000 in Elevance between April 18, 2024 and October 16, 2024......
16.05.25 - 11:48
 Actinium Pharmaceuticals, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before May 27, 2025 to Discuss Your Rights - ATNM (PR Newswire)
 
NEW YORK, May 16, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Actinium Pharmaceuticals, Inc. ("Actinium" or the "Company") (NYSE: ATNM) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Actinium investors who were......
15.05.25 - 11:48
 Class Action Filed Against Actinium Pharmaceuticals, Inc. (ATNM) - May 27, 2025 Deadline to Join - Contact The Gross Law Firm (PR Newswire)
 
NEW YORK, May 15, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Actinium Pharmaceuticals, Inc. (NYSE: ATNM). Shareholders who purchased shares of ATNM during the class period listed are encouraged to contact the firm regarding possible lead......
13.05.25 - 11:45
 Levi & Korsinsky Notifies Shareholders of Actinium Pharmaceuticals, Inc.(ATNM) of a Class Action Lawsuit and an Upcoming Deadline (PR Newswire)
 
NEW YORK, May 13, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Actinium Pharmaceuticals, Inc. ("Actinium" or the "Company") (NYSE: ATNM) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Actinium investors who were......
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Am Anfang war die Kraft. - Paula Modersohn-Becker
Partner:    >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!